Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 6/20 | 0.54 |
| ▸ | IL2 | P60568 | 4/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.37 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | GALR1 | P47211 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12377820 | 0.83 | NOTUM (0.55) | NOTUMIL2KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL17206755 | 0.81 | NOTUM (0.54) | NOTUMIL2KDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL2293084 | 0.81 | NOTUM (0.54) | NOTUMIL2KDM4EHPGDKMT2A | |
| SCHEMBL18121825 | 0.80 | NOTUM (0.70) | NOTUMIL2APPKDM4EHPGD | |
| SCHEMBL14007387 | 0.80 | NOTUM (0.69) | NOTUMIL2KDM4EHPGDKMT2A | |
| SCHEMBL2289458 | 0.77 | NPC1 (0.56) | NOTUMKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL20323164 | 0.71 | NOTUM (0.72) | NOTUMIL2KDM4EHPGDKMT2A | |
| SCHEMBL15205682 | 0.71 | NOTUM (0.65) | NOTUMIL2KDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL2731450 | 0.71 | NOTUM (0.56) | NOTUMIL2KDM4EHPGDKMT2A | |
| SCHEMBL13337104 | 0.71 | NOTUM (0.46) | NOTUMIL2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2163554-B1 | PYRIMIDODIAZEPINONE DERIVATIVE | KYOWA HAKKO KIRIN CO LTD (JP) | 2012-08-01 | — | — | EP | disclosed |
| US-7998954-B2 | Pyrimidodiazepinone derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20100190775-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-2163554-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2010-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190775-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | KCNJ1, KCNJ11, ADRA1D | NOTUM 3182/4885IL2 2525/4885APP 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.